BIOPHARMACEUTICAL COLD CHAIN ENGINEERING

Global Cold Chain Validation for Fast Track Regulatory Approval

Modality Solutions provides cold chain engineering, packaging qualification, drug product transport simulation and device functional testing for the biopharmaceutical industry. We design, calibrate, and validate your cold chain network to global regulatory standards. Our novel multi-variable transport simulation laboratory concurrently replicates the five key environmental hazards that impact product quality during transportation: temperature, shock, vibration, humidity, and pressure. Learn more at www.modality-solutions.com.

REGULATORY FILING SUPPORT 

Transport Simulation Laboratory

Thermal Package Engineering

Transport Validation 

COLD CHAIN OPERATIONS

Cold Chain Logistics

Clinical Trial Operations

 Technology

INTEGRATED EXPERTISE

Project Based

Staff Augmentation

Outsourced

Schedule your free one-hour, no obligation consultation.

If you work with us, this is what you can expect:

  • Confidence in your cold chain. Guaranteed.
  • Every engagement led by a principal.
  • Reach out anytime, anywhere, for anything.
  • We solve real problems. Your cold chain will be approved.
  • You will become a cold chain expert.

Let’s start a conversation! 

Call us today at (888) 219-6317

Email: info@modality-solutions.com 

Click here to schedule your free one-hour, no obligation consult.

Go to article: Home | A cure for a costGo to article: In this issueGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NewsGo to article: NSFGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: The value of real-world evidence during the Covid-19 outbreakGo to article: Covid-19: UK restricts parallel export of nearly 200 drugs, threatening its biopharma industryGo to article: Pharmaceutical professionals say employee safety and supply chain disruption are top Covid-19 concernsGo to article: AbbVie’s, Ascletis’ protease inhibitors spark skeptical outlook for repurposed activity in Covid-19Go to article: PhoenixGo to article: Phoenix Company InsightGo to article: The pharma industry briefingGo to article: No time to waste: repurposing drugs to tackle covid-19Go to article: How safe are simple painkillers?Go to article: Molnar Company Insight Go to article: Molnar-InstituteGo to article: Modelling the human body: a game changer for drug testing?Go to article: Pandemic pricing: existing drugs and price gougingGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Pandemic pricing: novel treatments and vaccinesGo to article: The dark side of anticoagulants: will a new approach shed light?Go to article: Zenatek Go to article: Finding a cure for HIV with ViiV Healthcare and UNC-Chapel HillGo to article: Disputing the facts: is the legal battle between Veeva and IQVIA an antitrust issueGo to article: Nelson LabsGo to article: Could nanoparticles unlock the pharmaceutical benefits of turmeric?Go to article: Why aren’t more companies automating PV data capture?Go to article: Modality SolutionsGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: ButterworthGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: MimotopesGo to article: EventsGo to article: Next issue